National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

octreotide acetate
The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:Longastatin
US brand names:Sandostatin
Sandostatin Lar Depot
Foreign brand names:Longastatina
Samilstin
Sandostatina
Sandostatine
Code name:SMS 201-995
Chemical structure name:7)-disulfide acetate



Previous:NY-ESO-1b peptide vaccine, NY-ESO-B, O6-benzylguanine, obatoclax mesylate, oblimersen sodium
Next:octreotide pamoate, odanacatib, Oestrogenine, Oestromenin, Oestromon

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov